|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 337.50 EUR | +0.30% |
|
-1.32% | -3.16% |
| 07-29 | Virbac, without the alibi |  |
| 07-21 | Virbac: Impressive execution in Q2; we smell a guidance upgrade in Q3 |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Veterinary Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 31.19B | |||||
| 13.1B | |||||
| 3.85B | |||||
| 3.27B | |||||
| 2.14B | - | - |
- Stock Market
- Stocks
- VIRP Stock
- V16 Stock
- Charts Virbac
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
